Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
166.6 ^USD	+1.59%		+25.57%	+67.53%

24/05	Novavax awaits FDA decision on whether its next COVID shot can be offered in US	RE
23/05	Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...

INTERVIEW - Stéphane Bancel, CEO of Moderna: towards $15 billion in annual revenues over the next few years

September 13, 2023 at 09:26 pm IST

Stéphane Bancel, Chairman and CEO of Moderna, talks about obtaining regulatory approval for a new version of its flu vaccine, and new ways of treating and detecting cancer, notably with messenger RNA technology.

(MT Newswires)

Bloomberg videos

Latest news about Moderna, Inc.

Novavax awaits FDA decision on whether its next COVID shot can be offered in US	25/05	RE
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	23/05
The market is good to go until Nvidia’s next quarterly results	23/05
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	23/05	DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET	23/05	DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	23/05	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	23/05	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	23/05	DJ
Health Care Up as Vaccine Makers Gain - Health Care Roundup	23/05	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	23/05	DJ
US IS IN 'ACTIVE CONVERSATIONS' WITH MRNA VACCINE MAKERS PFIZER…	23/05	RE
Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing	20/05	MT
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing	18/05	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	18/05	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	17/05	MT
Sector Update: Health Care	17/05	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	17/05	MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech	17/05	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	17/05	MT
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports	17/05	RE
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	17/05	MT
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner	17/05	RE
Merck to present new oncology data	15/05	CF
Investors need more than PPI to make up their minds	14/05
ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor...	14/05

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - Bernstein Strategic Decisions Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 07:54 pm IST

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 17, 2024 at 02:01 am IST

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

166.6 USD

Average target price

138.5 USD

Spread / Average Target

-16.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-8.12%	11.21B

Other Biotechnology & Medical Research